Recombinant Human TNFSF14 Protein, His-tagged

• Cat.No.: TNFSF14-150H
• Product Overview: Recombinant Human TNFSF14 Protein with His tag was expressed in E. coli.

Specification

• Description: Tumor necrosis factor superfamily member 14 (TNFSF14), also known as CD258 and LIGHT, is a cell surface type II transmembrane protein that is expressed as a homotrimer. The extracellular region can be cleaved to generate a soluble cytokine. TNFSF14 is a ligand for the receptors herpesvirus entry mediator (HVEM) and lymphotoxin receptor (LTR). TNFSF14 is expressed on activated NK cells, activated T cells, activated monocytes, immature DCs, and mast cells. TNFSF14 interactions with HVEM induce potent co-stimulatory signaling in T cells and trigger NK cells to produce IFN-γ via NF-κB RelA/p50 pathway signaling. TNFRSF14 produced by tumor-sensing NK cells aids in DC maturation, enabling de novo anti-tumor adaptive immune responses. TNFSF14-HVEM interactions are considered the main drivers of anti-tumor immune responses, whereas TNFSF14-LTR interactions have been characterized as maintaining the infrastructure that supports the anti-tumor response via lymphoid development and cancer cells’ susceptibility to the immune response. TNFSF14 induces the normalization of tumor vasculature, sensitizes tumor cells to IFN-γ-mediated apoptosis, and results in a more inflamed tumor microenvironment (TME). Due to its effects on the TME and anti-tumor immune cell responses, TNFSF14 is being investigated as a target for immunotherapeutic intervention in cancer. TNFSF14 has also been implicated in the development and pathogenesis of inflammatory bowel disease and airway remodeling leading to asthma.
• Source: E. coli
• Species: Human
• Tag: His
• Molecular Mass: ~20 kDa
• AA Sequence: LQLHWRLGEMVTRLPDGPAGSWEQL IQERRSHEVNPAAHLTGANSSLTGS GGPLLWETQLGLAFLRGLSYHDGAL VVTKAGYYYIYSKVQLGGVGCPLGL ASTITHGLYKRTPRYPEELELLVSQ QSPCGRATSSSRVWWDSSFLGGVVH LEAGEKVVVRVLDERLVRLRDGTRS YFGAFMV
• Purity: Transferred into competent cells and the supernatant was purified by NI column affinity chromatography and the purity is > 85% (by SDS-PAGE).
• Notes: For research use only, not for use in diagnostic procedure.
• Storage: Store at 4 centigrade short term. Aliquot and store at -20 centigrade long term. Avoid freeze-thaw cycles.
• Storage Buffer: PBS, 4M Urea, pH7.4

Gene Information

• Gene Name: TNFSF14 tumor necrosis factor (ligand) superfamily, member 14 [ Homo sapiens (human) ]
• Official Symbol: TNFSF14
• Synonyms: TNFSF14; tumor necrosis factor (ligand) superfamily, member 14; tumor necrosis factor ligand superfamily member 14; CD258; HVEM L; LIGHT; LTg; delta transmembrane LIGHT; herpesvirus entry mediator A; herpesvirus entry mediator ligand; herpesvirus entry mediator-ligand; herpes virus entry mediator ligand; ligand for herpesvirus entry mediator; tumor necrosis factor receptor-like 2; tumor necrosis factor superfamily member LIGHT; TR2; HVEML
• Gene ID: 8740
• mRNA Refseq: NM_003807
• Protein Refseq: NP_003798
• MIM: 604520
• UniProt ID: O43557

Reviews

07/28/2020

The extended longevity of results gave us the confidence to delve deeper into complex biological processes.

08/01/2018

It was reassuring to know that the product's effects persisted, allowing for thorough and comprehensive research.

06/19/2016

The ability to obtain enduring results positively influenced the depth of our investigations.

Q&As

What are the primary changes induced by TNFSF14 in the tumor microenvironment?

TNFSF14, when delivered to or expressed within tumors, causes significant changes primarily through vascular normalization and generation of tertiary lymphoid structures.

What challenges remain in utilizing TNFSF14 for cancer immunotherapy?

While investigators have used multiple vectors to deliver TNFSF14 to tumor tissues, there are still improvements needed, and components within the human tumor microenvironment may impede translational efforts.

What does TNFSF14 stand for?

TNFSF14 stands for Tumor Necrosis Factor Superfamily Member 14.

How can TNFSF14 synergize with other immunotherapy modalities?

TNFSF14's changes in the tumor microenvironment can synergize with methods inducing anti-tumor immune responses, such as checkpoint inhibitors and tumor vaccines, improving immunotherapeutic strategies against cancer.

In what context has TNFSF14 been utilized to combat cancer?

TNFSF14 has been used in multiple tumor models, where it can be combined with other immunotherapy modalities to clear established solid tumors and treat metastatic events.

How long has TNFSF14 been in pre-clinical development?

TNFSF14 has been in pre-clinical development for over a decade.

What is the primary promise of TNFSF14 in the field of cancer immunotherapy?

TNFSF14 shows promise in enhancing treatment approaches in cancer immunotherapy.